Aditya Bardia
MD, MPH
Director, Breast Oncology Research Program
👥Biography 个人简介
Aditya Bardia at Mass General Cancer Center led the ASCENT trial that established sacituzumab govitecan as a new standard of care for metastatic TNBC. His translational research has advanced TROP-2 as a therapeutic target and explored biomarkers of response to ADCs in breast cancer. He has pioneered combination studies pairing sacituzumab govitecan with checkpoint inhibitors and other targeted agents. His work has catalyzed the ADC revolution in breast cancer across multiple molecular subtypes.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Aditya Bardia 的研究动态
Follow Aditya Bardia's research updates
留下邮箱，当我们发布与 Aditya Bardia（Mass General Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment